Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vildagliptin, Liraglutide, and Empagliflozin for Fatty Liver in Type 2 Diabetes
NCT05041673Unknown
- Sponsor
- Alexandria University
- Start
- Feb 2021
- Primary completion
- Sep 2021
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of vildagliptin, liraglutide and empagliflozin in non-alcoholic fatty liver disease (NAFLD), sponsored by Alexandria University. Status: unknown.
02
Drugs
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT05041673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05041673.